| Literature DB >> 19814829 |
Donald R Noll1, Jane C Johnson2, Robert W Baer3, Eric J Snider4.
Abstract
BACKGROUND: The use of manipulation has long been advocated in the treatment of chronic obstructive pulmonary disease (COPD), but few randomized controlled clinical trials have measured the effect of manipulation on pulmonary function. In addition, the effects of individual manipulative techniques on the pulmonary system are poorly understood. Therefore, the purpose of this study was to determine the immediate effects of four osteopathic techniques on pulmonary function measures in persons with COPD relative to a minimal-touch control protocol.Entities:
Year: 2009 PMID: 19814829 PMCID: PMC2765983 DOI: 10.1186/1750-4732-3-9
Source DB: PubMed Journal: Osteopath Med Prim Care ISSN: 1750-4732
Figure 1Study outline.
Demographic characteristics of subjects (N = 25)*
| Sex | Atrovent updraft | ||
| Female | 11 (44%) | Yes | 8 (35%) |
| Male | 14 (56%) | No | 15 (65%) |
| Presently smoking | Type II DM | ||
| Yes | 9 (36%) | Yes | 4 (16%) |
| No | 16 (64%) | No | 21 (84%) |
| Prior OMT | History of stroke | ||
| Yes | 21 (84%) | Yes | 2 (8%) |
| No | 4 (16%) | No | 23 (92%) |
| Prior chiropractic treatment | History of heart failure | ||
| Yes | 22 (88%) | Yes | 2 (8%) |
| No | 3 (12%) | No | 23 (92%) |
| Preference: OMT or chiropractic | History of thyroid disease | ||
| OMT | 11 (58%) | Yes | 3 (12%) |
| No preference | 8 (42%) | No | 22 (88%) |
| Manipulation treatment for respiratory problem | History of pulmonary tuberculosis | ||
| Yes | 14 (56%) | No | 25 (100%) |
| No | 11 (44%) | ||
| Frequency of manipulative treatment | History of hypertension | ||
| More than 1 per year | 4 (16%) | Yes | 7 (28%) |
| One or less per year | 21 (84%) | No | 18 (72%) |
| Oxygen use | History of coronary heart disease | ||
| Yes | 12 (50%) | Yes | 7 (28%) |
| No | 12 (50%) | No | 18 (72%) |
| Theophylline use | History of pneumonia | ||
| Yes | 2 (8%) | Yes | 20 (80%) |
| No | 22 (92%) | No | 5 (20%) |
| Inhaled steroid use | History of asthma | ||
| Yes | 10 (42%) | Yes | 11 (44%) |
| No | 14 (58%) | No | 14 (56%) |
| Oral steroid use | History of cancer | ||
| Yes | 6 (26%) | Yes | 10 (40%) |
| No | 17 (74%) | No | 15 (60%) |
| Inhaled bronchodilator | History of CABG | ||
| Yes | 18 (75%) | Yes | 2 (8%) |
| No | 6 (25%) | No | 22 (92%) |
| Updraft treatments | History of lung surgery | ||
| Yes | 13 (52%) | Yes | 2 (8%) |
| No | 12 (48%) | No | 23 (92%) |
| Atrovent MDI | Family history of lung disease | ||
| Yes | 14 (58%) | Yes | 13 (54%) |
| No | 10 (42%) | No | 11 (46%) |
*Data are presented as number (% of subjects) for variables. Total counts may not add up to N due to missing values. All subjects were Caucasian.
OMT, osteopathic manipulative treatment; MDI, metered-dose inhaler; DM, diabetes mellitus; CABG, coronary artery bypass graft.
Baseline and posttreatment actual pulmonary function results for each technique
| FVC (L) | 2.79 ± 0.99 | 2.83 ± 1.05 | 2.75 ± 1.02 | 2.83 ± 1.02 | |
| 2.80 ± 0.97 | 2.79 ± 1.00 | 2.77 ± 1.05 | 2.79 ± 0.97 | ||
| FEV1 (L) | 1.57 ± 0.79 | 1.59 ± 0.82 | 1.63 ± 0.78 | 1.51 ± 0.79 | |
| 1.57 ± 0.79 | 1.58 ± 0.81 | 1.59 ± 0.75 | 1.53 ± 0.82 | ||
| FEV1/FVC (%) | 55 ± 13 | 54 ± 13 | 55 ± 13 | 53 ± 12 | 54 ± 12 |
| 54 ± 13 | 55 ± 14 | 55 ± 13 | 54 ± 13 | 53 ± 11 | |
| FEF25-75% (L/s) | 0.81 ± 0.62 | 0.80 ± 0.61 | 0.73 ± 0.52 | ||
| 0.78 ± 0.62 | 0.81 ± 0.59 | 0.77 ± 0.62 | |||
| FEFmax (L/s) | 4.55 ± 2.28 | 4.79 ± 2.35 | |||
| 4.41 ± 2.32 | 4.55 ± 2.27 | ||||
| Expiratory time (s) | 9.60 ± 1.63 | 9.54 ± 1.62 | 9.79 ± 2.52 | 10.00 ± 1.90 | 9.78 ± 1.74 |
| 9.74 ± 1.77 | 9.99 ± 2.60 | 9.29 ± 1.95 | 10.37 ± 2.08 | 10.06 ± 2.01 | |
| MVV (L/min) | 56 ± 30 | ||||
| 56 ± 30 | |||||
| SVC (L) | 2.91 ± 1.05 | 3.05 ± 1.10 | 2.82 ± 1.05 | ||
| 2.90 ± 1.14 | 2.98 ± 1.10 | 2.85 ± 1.12 | |||
| IC (L) | 2.10 ± 0.80 | 2.13 ± 0.79 | 2.00 ± 0.73 | 2.14 ± 0.77 | |
| 2.12 ± 0.76 | 2.09 ± 0.76 | 2.06 ± 0.78 | 2.10 ± 0.76 | ||
| ERV (L) | 0.77 ± 0.44 | 0.92 ± 0.51 | 0.82 ± 0.52 | 0.93 ± 0.55 | |
| 0.87 ± 0.62 | 0.89 ± 0.64 | 0.79 ± 0.52 | 0.86 ± 0.48 | ||
| TGV (L) | 4.14 ± 0.91 | 4.17 ± 0.88 | 4.29 ± 0.97 | 4.32 ± 1.13 | 4.35 ± 1.05 |
| 4.07 ± 0.90 | 4.18 ± 0.91 | 4.23 ± 1.03 | 4.16 ± 1.05 | 4.33 ± 1.08 | |
| RV (L) | 3.36 ± 0.81 | 3.38 ± 0.92 | 3.50 ± 1.21 | 3.41 ± 0.96 | |
| 3.19 ± 0.84 | 3.33 ± 0.99 | 3.37 ± 1.01 | 3.48 ± 1.08 | ||
| TLC (L) | 6.27 ± 1.16 | 6.27 ± 1.14 | 6.41 ± 1.11 | 6.32 ± 1.31 | 6.47 ± 1.23 |
| 6.10 ± 1.03 | 6.29 ± 0.99 | 6.33 ± 1.21 | 6.21 ± 1.14 | 6.44 ± 1.27 | |
| RV/TLC (%) | 54 ± 12 | 53 ± 13 | 55 ± 13 | 53 ± 13 | |
| 53 ± 13 | 53 ± 13 | 55 ± 14 | 54 ± 13 | ||
| Raw (cm H2O/L/s) | 4.09 ± 3.18 | 3.94 ± 3.15 | 4.30 ± 3.09 | 4.44 ± 3.17 | |
| 4.05 ± 2.76 | 3.94 ± 2.74 | 4.22 ± 3.11 | 4.06 ± 2.75 | ||
Results are reported as mean ± SD. Wilcoxon signed rank tests were used to test for significant baseline to posttreatment within-technique changes. Measures with significant within-technique changes are highlighted.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25-75%, average forced expiratory flow rate over the middle 50% of the FVC; FEFmax, maximum forced expiratory flow rate; MVV, maximal voluntary volume; SVC, slow vital capacity; IC, inspiratory capacity; ERV, expiratory reserve volume; TGV, total gas volume; RV, residual volume; TLC, total lung capacity; Raw, airway resistance.
Baseline and posttreatment percent predicted values for each technique
| FVC | 82 ± 22 | 83 ± 23 | 81 ± 22 | 82 ± 24 | |
| 82 ± 21 | 82 ± 21 | 82 ± 22 | 81 ± 23 | ||
| FEV1 | 58 ± 25 | 58 ± 24 | 56 ± 23 | ||
| 58 ± 24 | 58 ± 24 | 57 ± 25 | |||
| FEF25-75% | 29 ± 18 | 28 ± 17 | 26 ± 16 | ||
| 28 ± 18 | 29 ± 18 | 27 ± 19 | |||
| FEFmax | 70 ± 29 | ||||
| 68 ± 28 | |||||
| MVV | 52 ± 23 | ||||
| 52 ± 24 | |||||
| SVC | 79 ± 20 | 81 ± 23 | 77 ± 19 | ||
| 78 ± 22 | 79 ± 22 | 78 ± 21 | |||
| IC | 76 ± 21 | 77 ± 24 | 74 ± 19 | 77 ± 23 | |
| 78 ± 21 | 75 ± 21 | 76 ± 21 | 76 ± 21 | ||
| ERV | 80 ± 35 | 97 ± 48 | 87 ± 40 | 93 ± 45 | |
| 88 ± 47 | 92 ± 55 | 82 ± 40 | 87 ± 39 | ||
| TGV | 130 ± 30 | 131 ± 31 | 134 ± 34 | 136 ± 34 | 134 ± 33 |
| 127 ± 29 | 131 ± 31 | 132 ± 34 | 131 ± 34 | 134 ± 33 | |
| RV | 150 ± 41 | 151 ± 45 | 156 ± 54 | 152 ± 46 | |
| 143 ± 42 | 149 ± 48 | 151 ± 48 | 155 ± 48 | ||
| TLC | 106 ± 15 | 108 ± 17 | 108 ± 17 | 108 ± 16 | |
| 107 ± 15 | 106 ± 18 | 106 ± 16 | 108 ± 17 | ||
| Raw | 246 ± 175 | 234 ± 170 | 249 ± 192 | 275 ± 199 | |
| 243 ± 151 | 237 ± 157 | 250 ± 167 | 247 ± 153 | ||
Results are reported as mean ± SD. Wilcoxon signed rank tests were used to analyze for significant baseline to posttreatment within-technique changes. Measures with significant within-technique changes are highlighted.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25-75%, average forced expiratory flow rate over the middle 50% of the FVC; FEFmax, maximum forced expiratory flow rate; MVV, maximal voluntary volume; SVC, slow vital capacity; IC, inspiratory capacity; ERV, expiratory reserve volume; TGV, total gas volume; RV, residual volume; TLC, total lung capacity; Raw, airway resistance.
Baseline to posttreatment percent changes
| FVC | 0.7 ± 5.0 | 0.3 ± 11.9 | -1.4 ± 8.1 | 0.7 ± 8.3 | -0.7 ± 6.2 | 0.67 |
| FEV1 | 0.6 ± 6.6 | 0.2 ± 7.8 | -1.0 ± 7.8 | 1.2 ± 8.0 | -1.4 ± 6.8 | 0.10 |
| FEV1/FVC | -0.2 ± 5.3 | 0.3 ± 9.8 | 0.4 ± 4.0 | 0.7 ± 6.4 | -0.4 ± 5.3 | 0.71 |
| FEF25-75% | -2.4 ± 13.8 | 3.3 ± 23.4 | -5.5 ± 21.9 | 0.7 ± 22.5 | -7.3 ± 17.8 | 0.12 |
| FEFmax | -2.4 ± 14.5 | -6.3 ± 9.3 | -5.6 ± 12.6 | -6.1 ± 13.7 | -5.5 ± 17.3 | 0.25 |
| Expiratory time | 1.9 ± 11.4 | 5.0 ± 20.9 | -3.6 ± 12.4 | 5.2 ± 19.0 | 3.5 ± 15.5 | 0.48 |
| MVV | -0.0 ± 10.5 | -4.9 ± 10.7 | -4.6 ± 8.6 | -5.7 ± 10.1 | -5.7 ± 9.6 | 0.40 |
| SVC | -0.3 ± 7.7 | -3.2 ± 7.2 | -2.0 ± 7.4 | 0.6 ± 15.5 | -3.5 ± 6.3 | 0.51 |
| IC | -3.7 ± 9.9 | 2.5 ± 9.2 | -0.6 ± 10.6 | 2.7 ± 14.3 | -1.2 ± 10.1 | 0.21 |
| ERV | 10.9 ± 38.3 | -12.4 ± 31.3 | -6.9 ± 19.4 | 3.7 ± 59.8 | -1.1 ± 30.9 | 0.09 |
| TGV | -1.3 ± 8.2 | 0.6 ± 8.6 | -1.6 ± 8.0 | -3.2 ± 9.1 | -0.2 ± 7.2 | 0.19 |
| RV | -4.1 ± 17.4 | 3.2 ± 14.2 | -1.3 ± 12.4 | -1.9 ± 13.9 | 2.3 ± 11.1 | 0.10 |
| TLC | -2.2 ± 6.1 | 1.1 ± 7.2 | -1.4 ± 5.9 | -1.1 ± 5.7 | -0.5 ± 5.3 | 0.36 |
| RV/TLC | -2.4 ± 14.5 | 1.6 ± 10.1 | -0.2 ± 7.6 | -1.2 ± 10.4 | 2.8 ± 7.4 | 0.21 |
| Raw | 3.0 ± 27.5 | 5.9 ± 33.3 | 22.9 ± 46.1 | 1.2 ± 28.8 | 0.7 ± 30.9 | 0.53 |
Results are reported as mean ± SD. Friedman tests were used to test for differences between the techniques.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FEF25-75%, average forced expiratory flow rate over the middle 50% of the FVC; FEFmax, maximum forced expiratory flow rate; MVV, maximal voluntary volume; SVC, slow vital capacity; IC, inspiratory capacity; ERV, expiratory reserve volume; TGV, total gas volume; RV, residual volume; TLC, total lung capacity; Raw, airway resistance.
Reported study side effects surveyed by telephone the day after each treatment session*
| Subject | A | B | C | B | D |
| Reported Side Effect | PFT made sore for 2 or 3 days | Chest pain in middle for 24 hours | Soreness in front chest | Chest pain during the procedure | Soreness in chest for 1 day |
| Subject | E | F | F | G | |
| Reported Side Effect | Soreness in the chest, remains next day | Stiff neck and headache the next day | Tired back | During the treatment, not afterwards, sore in lower ribs near (old) surgery site | |
| Subject | H | I | J | ||
| Reported Side Effect | Chest pressure during treatment, pain for 2-3 days | Sore in chest later that night lasted until next day, and chest congestion | Pain during treatment, better afterwards, best so far | ||
| Subject | K | L | |||
| Reported Side Effect | Cramps in left lung | Discomfort across the back afterwards | |||
| 1 out of 18 | 4 out of 23 | 4 out of 21 | 3 out of 20 | 2 out of 16 | |
TLP, thoracic lymphatic pump; PFT, pulmonary function testing.
* Paraphrased from subjects' reports.
Subject perceptions of the treatment sessions surveyed by telephone the day after each session
| Do you believe your health has benefited from the most recent manipulation treatment you received in this study? | 41% | 76% | 67% | 68% | 53% |
| Do you feel that you breathed better after the most recent manipulation treatment you received in this study? | 44% | 74% | 57% | 79% | 50% |
| Did you enjoy receiving the most recent manipulation treatment in this study? | 71% | 86% | 80% | 88% | 88% |
| Would you recommend the most recent treatment to others? | 71% | 91% | 90% | 95% | 94% |
Subjects were asked to respond "Yes" or "No" to the questions in the table. Results are presented as the percentage of "Yes" responses and the total number of responses for each question.
TLP, thoracic lymphatic pump.